Antibodies used for the characterization of stable CHO transfectants
IgG (mouse)-FITC (isotype control), IgG (mouse)-PE (isotype control), CD38-FITC, CD40-PE, CD54-FITC, and CD56-PE were used from Beckman Coulter (Krefeld, Germany), mouse IgG2a PE-conjugated isotype control, anti-human CRACC-PE, anti-human IL-6R-PE, and antihuman FGFR3-PE from R & D Systems (Minneapolis, MN, USA). Anti-mouse IgG F(ab)2 fragment-FITC and mouse anti-human CD70 were purchased from SigmaAldrich (Munich, Germany) and AbD Serotec (Puchheim, Germany), respectively. TIB92 (mouse IgG2a) hybridoma supernatant was directly used as a control.
Cell growth inhibition experiments (MTS assay)
To evaluate the direct effects of TP15-Fc, target cells were seeded at a density of 2 x 10 4 cells/200 µl per well in 96-well-plates and incubated in the presence of 10 µg/ml of the respective antibody at 37 °C for 72 h. Vital cell mass was measured by a colorimetric method using MTS cell proliferation assay according to manufacturer's protocol (Promega). 4D5-Fc was used as control. Percent growth of antibody-treated cells was calculated compared to untreated cells.
Flow cytometric analyses to determine specific antigen binding site
ICAM-1 expression was quantified using saturating concentrations of 500 μg/ml of TP15-mFc and 4D5-mFc containing a murine IgG1 Fc (unpublished), respectively, and 0,5 x 10 6 indicated cells per sample with the QIFIKIT according to the manufacturer's instructions (DAKO, Denmark). Samples were analyzed on a flow cytometer (Navios; Beckman Coulter, Fullerton, CA). 
